Clinical Trials
7 trialsNCT06140524 2026-06-04
LINKER-MGUS1
Regeneron Pharmaceuticals
Phase 2 Recruiting
NCT01222286 2026-05-14
KIRMONO
Innate Pharma
Phase 2 Completed
NCT02316106 2026-04-23
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 2 Completed
NCT05955508 2026-04-13
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT01838369 2023-01-11
A Phase II Study of BI-505 in Smoldering Multiple Myeloma
BioInvent International AB
Phase 2 Terminated
NCT01302886 2020-12-17
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
Novartis
Phase 2 Completed
NCT01441973 2018-01-23
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Bristol-Myers Squibb
Phase 2 Completed